AchieveRx announced Q3 2026 results highlighting a corporate rebrand, strong 52-week clinical efficacy data for cytisinicline, and an on-track NDA resubmission as the company pivots to commercialization.
AchieveRx announced Q3 2026 results highlighting a corporate rebrand, strong 52-week clinical efficacy data for cytisinicline, and an on-track NDA resubmission as the company pivots to commercialization.